Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$94.67M$94.67M+28.7% vs Q2 2018 Net Income-$276.40M-$276.40MN/M vs Q2 2018 EPS Diluted-$3.74-$3.74N/M vs Q2 2018 Operating Income-$275,367,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$95,686,000N/M Margins · derivedOperating margin-290.9%−150.2 pt vs Q2 2018
Net margin-292.0%−143.4 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 7, 2019 · 38 d after period end